Statins to Prevent Cancer Associated Blood Clots

Patients with cancer are at high risk for life-threatening venous thromboembolism (VTE) yet rarely receive anticoagulant prophylaxis due to bleeding risks. Thus, effective prophylaxis in oncology requires a method to reduce VTE without increasing hemorrhage. The primary aim of the Statin Therapy to Prevent Cancer Associated Venous Thromboembolism (STAT-CAT) trial is to test whether rosuvastatin 20 mg daily for 12 months compared to placebo can safely prevent VTE in patients with newly diagnosed or recently relapsed cancer who are at increased thrombotic risk, are not planned to be anticoagulated, and who do not otherwise take statin therapy.

NCT Number	NCT07303816
Lead Sponsor	Brigham and Women's Hospital Collaborators: National Heart, Lung, and Blood Institute (NHLBI), Dana-Farber/Brigham and Women's Cancer Center
Conditions	Venous Thromboembolism, Cancer, Cardiovascular Events
Enrollment	4,000 participants
Start Date	2026-06-11
Primary Completion	2031-03-31 (estimated)
Study Completion	2032-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-12